MA (Oxon) BCL (Oxon) FRSPH FRSA MCIArb MTOPRA
Born on 15 July, 1986, in Budapest, Hungary and educated at Oxford and Cardiff, Chris von Csefalvay is a data scientist/computational epidemiologist focusing on infectious diseases and quantitative pharmacovigilance. His work on COVID-19 has been featured in a number of international media outlets and national television.
Following a career in corporate law and later in analysis, Chris von Csefalvay held a range of senior corporate data science roles, including as RB plc’s first Chief Data Scientist. An appointment to a senior data science position at Volkswagen’s Munich Data Lab followed, after which he worked in various senior roles in computational epidemiology for the healthcare industry. He was a founding partner and Head of Data Science and Medical Epidemiology of London-based global biosecurity consultancy CBRD. Since 2018, he has been serving as VP Special Projects of Starschema, a transatlantic IT professional services company headquartered in Arlington, VA, where he advises some of the world’s leading companies on getting value out of their data. His clients come predominantly, but not exclusively, from the healthcare, life sciences and pharmaceuticals sectors.
The author of numerous studies and research papers, he is a one-time winner of the Martin Wronker Prize at the University of Oxford, along with the Field Fisher Waterhouse Prize, the University College Prize and the Allen & Overy Prize. As a graduate student at Merton College, Oxford, he held both the Barnett Bequest and the Falcon Chambers scholarship, one of very few graduate students to have ever done so, followed by earning distinctions on both undergraduate and graduate work. Currently, he is a visiting lecturer in mathematics and machine learning at the Budapest University of Technology and Economics, where he is supervising several BSc thesis students every year.
He has been a Fellow of the Royal Society of Arts since 2015, and was elected Fellow of the Royal Society for Public Health in 2021, making him one of the youngest-ever FRSPHs. He is also a Member of The Association for Professionals in Regulatory Affairs and the Chartered Institute of Arbitrators.
Chris von Csefalvay’s artificial intelligence research is largely focused on computer vision, in particular applications of computer vision that involve medical imagery, from cytopathological specimens to the complexity of MRI scans and ultrasound recordings. His research in public health focuses on early isolation of pharmacovigilance signals, with a special emphasis on VAERS. You can read more about that here.
He does not have any social media other than Instagram and LinkedIn. Any Twitter accounts claiming to be him are impersonations, and best ignored.
In the media
- Mask Wars (City Journal)
- Distrust Is Infectious, Too (City Journal)
- Have the protests proved that Covid-19 risks are being vastly exaggerated? (The Spectator)
- What next for pandemic research? (Times Higher Education)
- The Unexamined Model is Not Worth Trusting (City Journal)
- The Price of Oppression (City Journal)
- Corona in den USA: Mediziner warnen nun vor Injektion von Desinfektionsmittel (Frankfurter Rundschau)
- COVID-19: Does sunlight rapidly destroy the coronavirus? (Gulf News)
- Trump will Äußerungen zu Desinfektionsmitteln nur “sarkastisch” gemeint haben (Arte)
- Sun Kills Virus; Scientists Divided (Manila Times)
- Does Sunlight Destroy the Coronavirus? (Barrons)
- A Remarkable Leap Forward (City Journal)
- Koronavírus: az USA-ban már használják, itthon még nem kellett a magyar cég adatelemző programja (Euronews)
- Open Season (City Journal)
- Facebook challenged over spread of anti-vaccine content in measles-stricken Samoa (RACGP)
- Vaccine campaign historic: epidemiologist (Samoa Observer)
- Horrible reality after measles epidemic (Samoa Observer)
From time to time, I am asked how to pronounce my name (I admit, it’s one of the less straightforward ones). There are roughly two main ways to pronounce my name, and both are equally valid. Myself and my wife both follow the first alternative. My dad uses the second.